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Cross disciplinary research has become routine at academic health centers be-cause larger teams with a broader range of skills are needed to solve complex health related problems.  Researchers routinely reach out to colleagues to un-
derstand how their work “at the bench” is, or could be, relevant to future clinical care, 
as well as, how to better incorporate what has been learned in a clinical trial into the 
community. To build effective teams, there are many “complexities” that must be an-
ticipated and/or addressed. 
The Complexities 
Some of the common complexities in-
volved in conducting cross disciplinary 
biomedical research are outlined below. 
Defining the Rules of Engagement
To form an effective team requires 
time and discussion. Even as the team is 
assembled and before the data is gath-
ered, teams should discuss rules on how 
the data will or will not be shared with 
others, could or could not be moved, and 
how each member will be acknowledged 
for their role in any published results. 
Who will write or lead each manuscript 
or grant requires frank discussions long 
before they are written or submitted. 
Vocabulary
As simple as it sounds, to form a 
functional team, an environment must 
be created where all members can be un-
derstood, and their ideas are welcomed. 
This starts with encouraging everyone 
to speak in words most can understand 
by avoiding terminology and acronyms 
specific to one discipline that might not 
be understood by others. This is also im-
portant if teams want to ever attract new 
members, including students. Vocabu-
lary goes beyond conversations. It also 
addresses how the data is captured and 
stored so that the data can be more easily 
shared. Using a common format, prefer-
ably an established vocabulary standard 
(e.g., SNOMED, LOINC) that includes 
meta-data to allow members to under-
stand how the fields are defined, for more 
consistent and reproducible data collec-
tion, as well as queries and analyses, or to 
combine with other data sets. Team mem-
bers with terminology expertise are very 
valuable, and team members who can 
translate between disciplines are essential 
to an effective multidisciplinary team. 
Data Transfer and Storage
Many teams require data to move from 
one place to another, like from a research 
instrument or electronic health record to a 
data storage space or a research database 
where the analysis will be performed. 
More teams are working with large re-
search files, terabytes or more, such as 
DNA sequencing data or image files (e.g., 
MRI or other anatomic imaging files) or 
data from large populations. These data 
sets often have to be stored in the cloud or 
in large data centers able to accommodate 
such large data, but moving files can be 
time and resource consuming. Large data 
sets often must be stored in their entirety 
at the point of creation until the full copy 
of the dataset is transported, stored and 
validated for completeness in its new lo-
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cation. Often discussions arise regarding 
“whose data is it”. Differences of opin-
ions need to be ironed out, including 
what federal or commercial entity rights 
or patient/research subject perceptions 
that might be involved. The cost of data 
storage is often underrecognized as well. 
How that cost will/will not be subsidized 
by the team members or grants must be 
determined and use of data steward(s) 
(e.g., personnel) to maintain and distrib-
ute data sets may be necessary to include 
in the cost structure.
Privacy and Security
The data storage vehicle depends in 
part on what data is being stored. Pro-
tected health information (PHI), Protect-
ed individual information (PII), as well 
as other sensitive data (e.g., student data, 
high security data) may require special 
controls for who can access the data and 
the ability to audit who has accessed the 
data. Data associated with an FDA appli-
cation or trial needs to meet FDA’s Title 
21 Code of Federal Regulations (CFR), 
Part 11 requirements. Many researchers 
are not as knowledgeable as they should 
be of the eighteen PHI identifiers defined 
by the HIPAA legislation (https://www.
hhs.gov/hipaa/index.html and shown in 
Table 1). As a result, researchers incor-
rectly believe their data is deidentified 
and attest as such, when the data is, in 
fact, still considered identifiable. 
Special Considerations with Global 
Sites, Teams or Focus
There are increasing, and often chang-
ing rules, when data, samples, equip-
ment, or team members move between 
or live in other countries. Countries have 
varying “export control” regulations con-
cerning what is or is not allowed to cross 
into or out of their country. For the US, 
this includes interactions with specific 
individuals whether located in another 
country or in the US and specific types 
of equipment. For many countries, this 
involves export of biologic samples or 
data. In particular, the new European 
Union Data Protection Regulation (EUD-
PR) introduced in 2016 requires anyone 
acquiring data in an EU country, even 
if acquired on the property of and from 
citizens of another country to meet spe-
cific standards and receive EU approval. 
These standards further apply to data 
moved from an EU country. 
Table 1: 18 PHI identifiers
• Names
• Dates, unless year alone
• Telephone numbers 
• Geographic data (address, full zip)
• FAX numbers 
• Social Security numbers 
• Email addresses
• Medical record number
• Health plan beneficiary numbers
• Account numbers
• Certificate/license numbers
• Vehicle identifiers and serial 
numbers including license plates
• Web URLs
• Device identifiers and serial 
numbers 
• Internet protocol addresses
• Full face photos or comparable 
images
• Biometric identifier (i.e. fingerprint)
• Any unique identifying number or 
code
Problem Solving
Teams will always encounter prob-
lems including personality disputes, in-
tellectual property disputes, ‘I contrib-
uted more than you did’ disputes, and 
‘but you promised me’ disputes, among 
others. Ideally, the team would have dis-
cussed potential conflicts as the team is 
developed, including how the team would 
anticipate solving conflicts and identify 
a structure, process, or person(s) within 
or outside the team to resolve disputes if 
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additional help is needed. Such a resolu-
tion strategy is often required in multi-PI 
grants by funding sponsors. These kinds 
of agreements are best documented and 
discussed for new teams so there is no 
misunderstanding later. If the team has 
not had such discussions, team leaders 
or members may need to reach out and 
find the best mediator after the fact, such 
as the research integrity officer or another 
senior leader that all parties agree to lis-
ten to for dispute resolution. Team leaders 
should be proactive—watching for signs 
of frustration or conflict and address is-
sues before they become impossible to 
resolve. Michelle Bennett, PhD, of the 
National Cancer Institute (NCI) assem-
bled a Field Guide for Collaboration and 
Team Science available on line that pro-
vides many practical approaches to com-
mon problems (https://www.cancer.gov/
about-nci/organization/crs/research-ini-
tiatives/team-science-field-guide/collabo-
ration-team-science-guide.pdf). 
Discussing Data Sharing with the 
Public
As time has passed, the public has seen 
more and more examples of times their 
data has been shared or “leaked” that they 
were not aware could occur. Many inves-
tigators believe sharing of de-identified 
data is acceptable and may even assume 
that no one would care. In fact, many indi-
viduals are comfortable with researchers 
sharing their personal data, even identi-
fied data, if they are informed in advance 
and have given their permission, such as 
through informed consent or broad con-
sent. However, others may feel different-
ly, even if their data is deidentified, hence 
the recent class action lawsuit or patients 
who objected to the University of Chica-
go Hospital who gave deidentified health 
data to Google as part of an artificial intel-
ligence project. These concerns can be pro-
actively addressed through the informed 
consent document, town hall meetings, 
or other public discussions about the im-
portance of the study and what the study 
is supposed to accomplish, or having a 
community advisory board of community 
leaders to be a sounding board about the 
methods to be used and help the investi-
gators disseminate the results when they 
are found. As researchers, if we do not 
have the public’s trust, we may not have 
funding long-term. We can all do a better 
job of discussing the value of the data and 
the project with the public and working 
with community leaders to implement the 
data into day-to-day healthcare or other 
outcomes.
Summary 
Team science is here to stay, and cu-
rating the datasets assembled by those 
teams needs to be discussed in advance. 
This is just one aspect of the complexi-
ties of conducting cross disciplinary bio-
medical research. Data sharing is usually 
good, often mandated by some funding 
mechanisms, is essential to multidisci-
plinary collaborations, and may result 
in even bigger datasets which can make 
moving and storing the data more chal-
lenging. The nuts and bolts of achieving 
data sharing, which may include data 
deidentification, moving large data sets, 
or loading data into a specific website can 
be confusing at best, and often difficult, 
as well. Data sharing may require new 
tools that are often developed with bio-
medical informatics experts, who are in 
too short of supply. Data sharing can cre-
ate new risks if those researchers who are 
sharing data are not aware of the pitfalls, 
particularly when PHI is involved. But 
lastly, we cannot forget the public, who 
needs to be part of the communication 
before data is shared and after, to bring 
them along, to understand the value, and 
to fully understand and make use of the 
results that are found. 
